Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates

Despite numerous endeavors in clinical trials there are few clinically approved Antibody Drug Conjugate (ADC) therapies. Here we comment on our recent publication demonstrating the power of using panels of patient-derived xenografts (PDX) prior to Phase 1, to assess the potential heterogeneity of re...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Scott David, Bialucha, Carl Uli, Williams, Juliet Anne, Gao, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791866/
https://www.ncbi.nlm.nih.gov/pubmed/29404392
http://dx.doi.org/10.1080/23723556.2017.1394422
Descripción
Sumario:Despite numerous endeavors in clinical trials there are few clinically approved Antibody Drug Conjugate (ADC) therapies. Here we comment on our recent publication demonstrating the power of using panels of patient-derived xenografts (PDX) prior to Phase 1, to assess the potential heterogeneity of response a clinical candidate may show across a population. Furthermore we discuss how the same approach has been used in an additional ADC program.

Ejemplares similares